BRPI0920573A2 - complexos tcr imunoterapêuticos - Google Patents
complexos tcr imunoterapêuticosInfo
- Publication number
- BRPI0920573A2 BRPI0920573A2 BRPI0920573A BRPI0920573A BRPI0920573A2 BR PI0920573 A2 BRPI0920573 A2 BR PI0920573A2 BR PI0920573 A BRPI0920573 A BR PI0920573A BR PI0920573 A BRPI0920573 A BR PI0920573A BR PI0920573 A2 BRPI0920573 A2 BR PI0920573A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunotherapeutic
- tcr complexes
- tcr
- complexes
- immunotherapeutic tcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10460808P | 2008-10-10 | 2008-10-10 | |
| US14834109P | 2009-01-29 | 2009-01-29 | |
| PCT/US2009/060286 WO2010042904A2 (en) | 2008-10-10 | 2009-10-09 | Tcr complex immunotherapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0920573A2 true BRPI0920573A2 (pt) | 2015-12-29 |
| BRPI0920573A8 BRPI0920573A8 (pt) | 2017-12-12 |
Family
ID=41650152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920573A BRPI0920573A8 (pt) | 2008-10-10 | 2009-10-09 | Complexos tcr imunoterapêuticos |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20110217302A1 (pt) |
| EP (1) | EP2356150A2 (pt) |
| JP (3) | JP2012504970A (pt) |
| KR (2) | KR20180105736A (pt) |
| CN (2) | CN102292352A (pt) |
| AU (1) | AU2009303318B2 (pt) |
| BR (1) | BRPI0920573A8 (pt) |
| CA (1) | CA2740098A1 (pt) |
| EA (1) | EA032828B1 (pt) |
| MX (1) | MX2011003763A (pt) |
| NZ (2) | NZ592611A (pt) |
| SG (1) | SG172754A1 (pt) |
| WO (1) | WO2010042904A2 (pt) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| MX2011000071A (es) * | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| NO2344540T3 (pt) | 2008-10-02 | 2018-04-28 | ||
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| AU2010325969B2 (en) | 2009-12-02 | 2016-10-20 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen |
| WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| JP5764921B2 (ja) | 2009-12-24 | 2015-08-19 | Jnc株式会社 | 発光活性を有する融合蛋白質 |
| CA2785907A1 (en) * | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EA201390472A1 (ru) | 2010-10-29 | 2014-02-28 | Иммьюноджен, Инк. | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты |
| EA201390575A1 (ru) * | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| EP2699596A4 (en) * | 2011-04-22 | 2015-01-14 | Emergent Product Dev Seattle | PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| BR112014010532A2 (pt) | 2011-11-03 | 2017-04-18 | Tolera Therapeutics Inc | anticorpo e métodos para inibição seletiva de respostas de célula-t |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| CA2856411A1 (en) | 2011-11-21 | 2013-05-30 | Immunogen, Inc. | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| EP3202783A1 (en) | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| EP3593136A1 (en) * | 2017-03-06 | 2020-01-15 | Talaris Therapeutics, Inc. | Methods and compositions for determining the potency of a therapeutic cellular composition |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| JP7164596B2 (ja) * | 2017-08-28 | 2022-11-01 | システィミューン， インク． | 抗ｃｄ３抗体とその作製及び使用方法 |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| AR115730A1 (es) * | 2018-07-10 | 2021-02-17 | Regeneron Pharma | Modificación de moléculas de unión para minimizar interacciones pre-existentes |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2022003507A (es) * | 2019-09-25 | 2022-04-25 | Univ Stuttgart | Modulos de union que comprenden dominios ehd2 modificados. |
| CN113005088B (zh) * | 2019-12-19 | 2024-06-04 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| US20230123454A1 (en) * | 2020-01-23 | 2023-04-20 | Genexine, Inc. | Fusion protein comprising pd-l1 protein and use thereof |
| CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| ATE277081T1 (de) * | 1994-01-11 | 2004-10-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| ATE283925T1 (de) * | 1996-07-23 | 2004-12-15 | Tanox Pharma B V | Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann |
| PT1049787E (pt) * | 1998-01-23 | 2005-04-29 | Vlaams Interuniv Inst Biotech | Derivados de anticorpos multipropositos |
| AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20040044182A1 (en) * | 2001-09-17 | 2004-03-04 | Hunt Joan S | Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g |
| EP1553975B8 (en) * | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| EP2433650A3 (en) * | 2006-06-06 | 2012-12-19 | Tolerrx Inc. | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| SG177907A1 (en) * | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| CA2673470A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| JP2010532764A (ja) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| MX2011000071A (es) * | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| CA2732574A1 (en) * | 2008-07-28 | 2010-02-04 | Philip Tan | Multi-specific binding proteins targeting b cell disorders |
| NO2344540T3 (pt) * | 2008-10-02 | 2018-04-28 | ||
| WO2011079308A2 (en) * | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
-
2009
- 2009-10-09 AU AU2009303318A patent/AU2009303318B2/en not_active Ceased
- 2009-10-09 WO PCT/US2009/060286 patent/WO2010042904A2/en not_active Ceased
- 2009-10-09 JP JP2011531236A patent/JP2012504970A/ja active Pending
- 2009-10-09 KR KR1020187026738A patent/KR20180105736A/ko not_active Ceased
- 2009-10-09 CN CN2009801500257A patent/CN102292352A/zh active Pending
- 2009-10-09 NZ NZ592611A patent/NZ592611A/xx not_active IP Right Cessation
- 2009-10-09 KR KR1020117010643A patent/KR101901458B1/ko active Active
- 2009-10-09 US US13/123,509 patent/US20110217302A1/en not_active Abandoned
- 2009-10-09 SG SG2011025608A patent/SG172754A1/en unknown
- 2009-10-09 CA CA2740098A patent/CA2740098A1/en not_active Abandoned
- 2009-10-09 NZ NZ603623A patent/NZ603623A/en not_active IP Right Cessation
- 2009-10-09 CN CN201510679112.9A patent/CN105218673A/zh active Pending
- 2009-10-09 MX MX2011003763A patent/MX2011003763A/es not_active Application Discontinuation
- 2009-10-09 EP EP09740584A patent/EP2356150A2/en not_active Withdrawn
- 2009-10-09 BR BRPI0920573A patent/BRPI0920573A8/pt active Search and Examination
- 2009-10-09 EA EA201170475A patent/EA032828B1/ru not_active IP Right Cessation
-
2013
- 2013-03-14 US US13/830,959 patent/US20130189261A1/en not_active Abandoned
-
2014
- 2014-09-04 JP JP2014179868A patent/JP5955913B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-10 US US15/040,744 patent/US20170008960A1/en not_active Abandoned
- 2016-04-13 JP JP2016080105A patent/JP2016145244A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2740098A1 (en) | 2010-04-15 |
| MX2011003763A (es) | 2011-04-27 |
| NZ603623A (en) | 2014-05-30 |
| CN102292352A (zh) | 2011-12-21 |
| AU2009303318A1 (en) | 2010-04-15 |
| EP2356150A2 (en) | 2011-08-17 |
| JP2012504970A (ja) | 2012-03-01 |
| KR101901458B1 (ko) | 2018-09-21 |
| AU2009303318A2 (en) | 2011-11-10 |
| US20130189261A1 (en) | 2013-07-25 |
| JP5955913B2 (ja) | 2016-07-20 |
| US20110217302A1 (en) | 2011-09-08 |
| WO2010042904A2 (en) | 2010-04-15 |
| NZ592611A (en) | 2013-01-25 |
| CN105218673A (zh) | 2016-01-06 |
| KR20180105736A (ko) | 2018-09-28 |
| EA032828B1 (ru) | 2019-07-31 |
| SG172754A1 (en) | 2011-08-29 |
| JP2014227419A (ja) | 2014-12-08 |
| WO2010042904A3 (en) | 2010-08-19 |
| JP2016145244A (ja) | 2016-08-12 |
| EA201170475A1 (ru) | 2012-06-29 |
| KR20110074900A (ko) | 2011-07-04 |
| AU2009303318B2 (en) | 2016-06-30 |
| BRPI0920573A8 (pt) | 2017-12-12 |
| US20170008960A1 (en) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920573A2 (pt) | complexos tcr imunoterapêuticos | |
| EP2116827A4 (en) | SPECTROSCOPE | |
| EP2305405A4 (en) | COATED ELEMENT | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| EP2307460A4 (en) | MINERAL AMINO ACID POLYSACCHARIDE COMPLEX | |
| EP2123638A4 (en) | METAL COMPLEX | |
| BRPI0908757A2 (pt) | motor | |
| BRPI0908554A2 (pt) | motor | |
| BRPI0920863A2 (pt) | motor | |
| FR2935592B1 (fr) | Poudrier | |
| EP2306469A4 (en) | Ptc device | |
| DE112009001577A5 (de) | Verstellpumpe | |
| CY2022026I2 (el) | Συμπλοκα πρωτεϊνων-πολυμερων | |
| BRPI0920864A2 (pt) | motor | |
| EP2339366A4 (en) | DEVICE FOR OPTICAL DISTANCE MEASUREMENT | |
| DK2257164T3 (da) | Herbicid-kombinationer indeholdende diflufenican | |
| BRPI0909626A2 (pt) | motor | |
| FR2940007B1 (fr) | Taille-haie | |
| DK2254963T3 (da) | Kerne-skal-flowforbedrer | |
| DE102008047798A8 (de) | Einband | |
| DE502008003019D1 (de) | Einschraubverschraubung | |
| ES1067763Y (es) | Dendrometro | |
| BRPI0913712A2 (pt) | motor | |
| FI11277U1 (fi) | Puuviilulevy | |
| FI20080325A0 (fi) | Pihkaliuos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |